Navigation Links
EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
Date:3/25/2008

ROCKVILLE, Md., March 25 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that James S. Burns, President and Chief Executive Officer, will present a Corporate overview at the BioCentury Future Leaders in the Biotech Industry Conference, to be held at the Millennium Broadway Hotel & Conference Center, March 27, 2008. Mr. Burns' presentation is scheduled for Thursday, March 27, 2008 at 4:00 p.m. (local time).

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Mr. Burns' live presentation will be web cast and can be accessed through the Company's web site at http://www.entremed.com. An archive will be available on the web site for approximately 90 days.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is an oral cell-cycle regulator with activity against the mTOR pathway. ENMD-1198, a novel antimitotic agent, is in a Phase 1 study in advanced cancer patients, and ENMD-2076, a selective kinase inhibitor, is expected to begin a Phase 1 study in 2Q08. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases,
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. EntreMed Announces 2008 Corporate and Clinical Program Priorities
2. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
3. EntreMed to Present at BIO CEO and Investor Conference
4. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
5. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
6. EntreMed Appoints Senior Vice President of Research and Development
7. EntreMed to Present at ThinkEquity Partners 5th Annual Growth Conference
8. Osteotech to Present at the Sidoti Conference in New York
9. BioMS Medical to present at BioCentury Conference
10. Biodel Inc. to Present at the BioCentury Future Leaders Conference on March 27th, 2008
11. Evotec AG: Fiscal Year 2007 Results Presentation on March 28, 2008 Live on the Internet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Los Angeles, CA (PRWEB) July 10, 2014 ... Analytical and Bioanalytical techniques during 18-20 August, 2014 at ... to critically review the recent developments in Analytical & ... across the globe. , Speaking on this occasion, Dr. ... that Analytica Acta conference is a remarkable one ...
(Date:7/10/2014)... , July 10, 2014  Kainos Capital, a firm ... today announced that it has acquired the Slim-Fast brand ... the business. Terms of the transaction were not disclosed. ... meal replacement business that markets ready-to-drink shakes, powders, bars ... America and in the United ...
(Date:7/10/2014)... help in the fight against terrorism with the creation ... explosives with the use of light and special glass ... Actuators B: Chemical , the researchers describe a novel ... as low as 6.3 ppm (parts per million). It ... , "Traditionally explosives detection has involved looking for metals ...
(Date:7/10/2014)... batteries that power our laptops and electric vehicles could ... charge with the help of a sponge-like silicon material. ... the graphite traditionally used in one of the battery,s ... energy storage capacity of graphite. A paper describing the ... today in Nature Communications . , "Silicon has ...
Breaking Biology Technology:A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Kainos Capital Acquires Slim-Fast From Unilever 2Detecting trace amounts of explosives with light 2Silicon sponge improves lithium-ion battery performance 2Silicon sponge improves lithium-ion battery performance 3
... the diuretic hydrochlorothiazide (HCTZ) in ... in significant additional blood pressure reductions compared to either drug alone ... or more, medicines - single-tablet combinations simplify treatment by reducing ... number of pills patients take, EAST ...
... Named ,Illinois Rising Stars, CHICAGO, Jan. 18 ... property law firms in the United States, is,pleased to ... "Illinois,Super Lawyers" for 2008 in a survey conducted by ... designated "Rising Stars" in,Illinois., Meredith Martin Addy, chair ...
... Jan. 18 Abbott (NYSE: ABT ),announced today ... for its fully automated HTLV-I/HTLV-II blood screening test,for use ... for use by,laboratories to screen individual donations of blood ... Type I and/or human T --,lymphotropic virus Type II ...
Cached Biology Technology:Video and Photo: Tekturna HCT(R), a Single-tablet Combination of Tekturna(R)* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure 2Video and Photo: Tekturna HCT(R), a Single-tablet Combination of Tekturna(R)* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure 3Video and Photo: Tekturna HCT(R), a Single-tablet Combination of Tekturna(R)* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure 4Video and Photo: Tekturna HCT(R), a Single-tablet Combination of Tekturna(R)* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure 5Twenty-One Brinks Hofer Gilson & Lione Attorneys Named 2008 'Illinois Super Lawyers' 2Abbott Announces Approval of First Fully Automated Blood Screening Test for HTLV-I/HTLV-II 2Abbott Announces Approval of First Fully Automated Blood Screening Test for HTLV-I/HTLV-II 3
(Date:7/11/2014)... evidence has demonstrated that transplantation of mesenchymal stem cells ... or mouse models of Alzheimer,s disease (AD) and improve ... ischemia. Few studies are reported on the therapeutic effect ... AD and on the effect on oxidative injury and ... Yan and her team, School of Life Sciences, Tsinghua ...
(Date:7/11/2014)... that cannabinoid receptor type 1 can inhibit ... and reduce neurotransmitter release. However, some scholars ... increase extracellular Ca2+ influx and increase neurotransmitter ... Tongji Hospital Affiliated to Tongji Medical College, ... used whole cell voltage-clamp and calcium imaging ...
(Date:7/11/2014)... brains of all vertebrates, information is transmitted through ... chemical signal to be passed from one brain ... most abundant type of synapse, can be either ... learning, memory, perception and cognition, and the balance ... function. For instance, every time we learn ...
Breaking Biology News(10 mins):Blame it on the astrocytes 2
... May 3, 2010-Conventional agriculture production relies heavily on fossil ... a low cost. However, the uncertain future of fossil ... energy efficiencies in other cropping systems. Most of ... of corn and soybean with heavy inputs of fertilizer, ...
... May 3, 2010 Genes interact in complex networks that ... through relationships. Researchers are now discovering how biological networks ... published today in Genome Research ( www.genome.org ), ... shedding light on how interactions go awry in disease. ...
... May 2 Scientists at the University of Pittsburgh School ... a catch of new mediators that not only can explain ... novel treatments for a host of diseases linked to inflammatory ... of Nature Chemical Biology . There is strong ...
Cached Biology News:Reducing fossil energy use on the farm 2Reducing fossil energy use on the farm 3MicroRNA network study implicates rewired interactions in cancer 2Pitt pharmacologists go on a molecular fishing trip and hook prize catch 2